PSMA Radioligand Therapy in Prostate Cancer: Where Are We and Where Are We Heading?

Abstract: Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.
Competing Interests: Conflicts of interest and sources of funding: K.H. reports personal fees and other from Sofie Biosciences; nonfinancial support from ABX; grants and personal fees from BTG; and personal fees from Bayer, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, Fusion, Immedica, Onkowissen.de, Novartis, Molecular Partners, Y-mAbs, Aktis Oncology, Theragnostics, Pharma15, Debiopharm, AstraZeneca, and Janssen. B.H. reports grants to institution from Novartis, BMS, and the German Research Foundation; consulting fees from ABX, Amgen, AstraZeneca, Bayer, BMS, Janssen, Lightpoint Medical, and Pfizer; payment for lectures from Janssen; support for travel or attending meetings from Bayer and Janssen; and participation on data safety monitoring boards for Janssen. The rest of the authors report that they have no conflict of interest.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)